Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Capecitabine 31 Oxaliplatin 29 Fluorouracil 27 Leucovorin 24 Irinotecan 21 Bevacizumab 18 Radiotherapy 14 Cetuximab 14 Radiation 8 Surgical Procedures, Operative 6 Radiotherapy, Intensity-Modulated 5 Chemotherapy, Adjuvant 5 Neoadjuvant Therapy 4 Immunohistochemistry 4 Gene Expression Profiling 4 cediranib 3 Folfox protocol 3 Celecoxib 3 Biopsy 3 Amplified Fragment Length Polymorphism Analysis 3 regorafenib 2 Surveys and Questionnaires 2 Reverse Transcriptase Polymerase Chain Reaction 2 Receptor Protein-Tyrosine Kinases 2 Proctectomy 2 Polymerase Chain Reaction 2 Mitomycin 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 Floxuridine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡